ストックスクリーナーアプリを入手
1.50
1.35%
0.02
前日終値:
$1.48
開ける：
$1.48
24時間の取引高:
149.12K
Relative Volume:
0.80
時価総額：
$151.62M
収益：
-
当期純損益:
$-60.14M
株価収益率:
-2.1142
EPS:
-0.7095
ネットキャッシュフロー:
$-68.17M
1週間 パフォーマンス:
-0.66%
1か月 パフォーマンス:
-28.57%
6か月 パフォーマンス:
-51.77%
1年 パフォーマンス:
-38.02%
1日の値動き範囲:
$1.46
$1.51
1週間の範囲:
$1.45
$1.5399
52週間の値動き範囲:
$1.4299
$4.9782
Ac Immune Sa Stock (ACIU) Company Profile
ACIU を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACIU
Ac Immune Sa
|
1.50 | 151.62M | 0 | -60.14M | -68.17M | -0.7095 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Ac Immune Sa Stock (ACIU) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-05-31 | 開始されました | BTIG Research | Buy |
| 2019-02-01 | ダウングレード | UBS | Buy → Neutral |
| 2019-01-04 | 開始されました | UBS | Buy |
| 2018-04-05 | 開始されました | H.C. Wainwright | Buy |
| 2018-03-23 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2016-10-18 | 開始されました | Credit Suisse | Outperform |
| 2016-10-18 | 開始されました | Jefferies | Buy |
| 2016-10-18 | 開始されました | Leerink Partners | Outperform |
すべてを表示
Ac Immune Sa (ACIU) 最新ニュース
Q2 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
Q1 Earnings Estimate for AC Immune Issued By Leerink Partnrs - Defense World
AC Immune unveils first-in-class Morphomer targeting pathological α-synuclein - BioWorld MedTech
HC Wainwright Reiterates “Buy” Rating for AC Immune (NASDAQ:ACIU) - Defense World
AC Immune SA: Promising Phase 2 Results and Positive Outlook Drive Buy Rating - TipRanks
AC Immune reports interim outcomes from trial of Parkinson’s therapy - Yahoo Finance
AC Immune (ACIU) Shares Surge on Promising Parkinson's Trial Res - GuruFocus
AC Immune reports Phase II trial of ACI-7104.056 - The Pharma Letter
AC Immune’s Strategic Advances and Financial Highlights - TipRanks
AC Immune Announces Positive Interim Data From Early Parkinson's Disease Study - Nasdaq
AC Immune stock gains on Parkinson’s data (ACIU:NASDAQ) - Seeking Alpha
AC Immune announces additional data from Phase 2 study of VacSYn clinical trial - TipRanks
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease - The Manila Times
AC Immune SAACI-7104.056 Is Well Tolerated With No Safety Issues Reported To Date - MarketScreener
AC Immune Reports Further Positive Interim Results from - GlobeNewswire
AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease - Yahoo
Benign Growth For AC Immune SA (NASDAQ:ACIU) Underpins Stock's 26% Plummet - simplywall.st
Short Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9% - Defense World
AC Immune To Showcase Innovations In Active Immunotherapies - Evrim Ağacı
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 - GlobeNewswire
AC Immune SA to Highlight Advanced Immunotherapy Pipeline at AD/PD™ 2025 Conference - Nasdaq
ACIU Stock Crashes 18.3% in a Month: Buy, Sell or Hold? - Zacks Investment Research
Promising Developments in AC Immune SA’s ACI-7104 Program Drive Buy Rating - TipRanks
AC Immune: Promising Pipeline and Financial Stability Drive Buy Rating - TipRanks
AC Immune (NASDAQ:ACIU) investors are sitting on a loss of 52% if they invested five years ago - Yahoo Finance
AC Immune (NASDAQ:ACIU) Earns “Buy” Rating from HC Wainwright - Defense World
AC Immune SA reports results for the quarter ended December 31Earnings Summary - TradingView
AC Immune SA Reports 2024 Financial Results and Strategic Advances - TipRanks
AC Immune reports FY24 EPS (51c), consensus (54c) - TipRanks
AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update - The Manila Times
AC Immune SA Reports 2024 Financial Results and Announces Takeda Partnership for ACI-24.060 - Nasdaq
AC Immune Lands Massive $2.1B Potential Deal with Takeda, Extends Cash Runway to 2027 - StockTitan
AC Immune (ACIU) Projected to Post Quarterly Earnings on Thursday - Defense World
New Strong Buy Stocks for March 5th - Nasdaq
AC Immune to Participate in Upcoming Investor Conferences - GlobeNewswire
AC Immune Management Team Opens Door to Investors at Two Major Healthcare Conferences - StockTitan
AC Immune: Leader In Dementia Therapies, A Space Littered With Failures (ACIU) - Seeking Alpha
Contrasting Silence Therapeutics (NASDAQ:SLN) & AC Immune (NASDAQ:ACIU) - Defense World
Alzheimer's Disease Clinical Trial Pipeline | 110+ Companies Pioneering Breakthroughs in Treatment | - EIN News
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. To Its Board - citybiz
Down -9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in AC Immune (ACIU) - Yahoo Finance
AltPep Corporation Appoints Alan Colowick, M.D., M.P.H. to Board of Directors - Business Wire
Leerink Partnrs Predicts Increased Earnings for AC Immune - MarketBeat
3 US Penny Stocks With Market Caps Over $100M To Consider - Simply Wall St
Leerink Partnrs Increases Earnings Estimates for AC Immune - Defense World
New Strong Buy Stocks for January 31st - Yahoo Finance
Updates in Therapeutic Development: Clinical Trial Readouts to Watch in the First Half of 2025 - Neurology Live
Five promising small-cap pharmaceutical companies taking on Alzheimer’s - Kursiv Media
Ac Immune Sa (ACIU) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):